I started out as a cardiovascular primary care sales rep with Merck in the UK.
Julia Walker
Senior Director, Brand Corporate Affairs, AstraZeneca
I started out as a cardiovascular primary care sales rep with Merck in the UK. During that time, the results of the landmark 4S study [Scandinavian Simvastatin Survival Study] made major news on front pages and broadcast outlets around the world. That was my first real taste for what public relations could do and what it was all about. My agency experience really afforded me the best opportunity to get to know our key stakeholder: the media.
I'm most proud of the work I've done on our cholesterol-lowering, atherosclerosis-slowing statin, Crestor. Specifically, the work done by our brand corporate affairs team was a key reason AstraZeneca was able to shift its communications strategy from one of a defensive posture to a more proactive, results-oriented approach. Ultimately, transparent communication of the scientific data for Crestor helped prove the various allegations being made were indeed misleading and inaccurate. Now, thanks to a well-coordinated awareness and education effort, Crestor is helping millions of patients lower their cardiovascular risk, and is the only branded statin that continues to gain market share.
All leaders, at some point in their professional (and probably personal) lives, have operated under the philosophy of "if you want it done right, do it yourself." I'm certainly no exception to that rule. Avoidance of micromanaging is the hardest part of the transition from being a doer to being a manager. The team I've helped build and the agency partners in which I've put my trust have made it easier for me to let go. Still, that doesn't just happen at the drop of a hat. It takes a great deal of work to nurture and mentor a team to be ready to take on roles and responsibilities that you would otherwise handle yourself.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.